Lavezzo A, Manzoni L, Aureggi G, Nisato D, Bianchetti A, Carminati P
Int J Tissue React. 1984;6(2):155-65.
The pharmacological activity of CM 57755, a new gastric antisecretory compound of the anti-H2 type, was studied in certain in vivo and in vitro preparations. In stomach-lumen perfused rats it proved to be, on a molar basis, half as active as cimetidine and 1/13 as active as ranitidine in inhibiting histamine-induced gastric acid secretion. On the other hand, CM 57755 administered to conscious gastric-fistula cats, either i.v. or intragastrically, depressed the hypersecretory plateau evoked by constant infusion of dimaprit with a potency comparable to that of cimetidine. In this preparation, the inhibition at equieffective doses of antagonists was more sustained for CM 57755 than for cimetidine and ranitidine. Applied to isolated guinea-pig right atria and gastric mucosa, CM 57755 competitively antagonized histamine effects (respective pA2's: 5.4 and 5.9) but was less potent than expected from its in vivo antisecretory activity. Bioavailability and/or biotransformation are the factors most likely to account for the differences observed between species, and between in vivo and in vitro studies for this long-acting antisecretory agent.
新型抗H2型胃泌素分泌化合物CM 57755的药理活性在某些体内和体外制剂中进行了研究。在胃腔灌注大鼠中,以摩尔为基础,它在抑制组胺诱导的胃酸分泌方面的活性仅为西咪替丁的一半,雷尼替丁的1/13。另一方面,给清醒的胃瘘猫静脉注射或胃内给予CM 57755,可抑制由持续输注地马普明引起的高分泌平台,其效力与西咪替丁相当。在该制剂中,与西咪替丁和雷尼替丁相比,CM 57755在等效剂量下的抑制作用更持久。应用于离体豚鼠右心房和胃黏膜时,CM 57755竞争性拮抗组胺作用(各自的pA2值:5.4和5.9),但其效力低于根据其体内抗分泌活性预期的效力。生物利用度和/或生物转化最有可能是造成该长效抗分泌剂在不同物种之间以及体内和体外研究之间观察到差异的因素。